Alto Neuroscience, Inc. (ANRO)

13.85 -0.31 (-2.16%) As of 03:01PM EDT. Market open.

Alto Neuroscience, Inc.

369 South San Antonio Road
Los Altos, CA 94022
United States
650 200 0412
https://www.altoneuroscience.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Amit Etkin M.D., Ph.D.	Founder, Chairman of the Board, CEO & President	705.65k	N/A	1977
Mr. Nicholas C. Smith	CFO & Secretary	624.12k	N/A	1989
Mr. Adam Savitz M.D., Ph.D.	Chief Medical Officer	579.57k	N/A	1966
Ms. Melissa Berman	Vice President of Finance & Accounting	N/A	N/A	1980
Ms. Erin R. McQuade J.D.	General Counsel & Chief Administrative Officer	N/A	N/A	1975
Ms. Jessica Powell	Chief Development Officer	N/A	N/A	1975
Mr. Fadi Abdel M.D.	Senior Vice President of Innovation	N/A	N/A	1979

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Corporate governance

Alto Neuroscience, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.